The use of recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer.
Skarulis
M C
MC
Division of Intramural Research, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive MSC 1771, Building 10 Room 8S235B, Bethesda, MD 20892-1771, USA. monica_skarulis@nih.gov
D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D011788:Quality of Life; D011994:Recombinant Proteins / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D013954:Thyroglobulin / Q000097:blood; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D013972:Thyrotropin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*
D007457:Iodine Radioisotopes; D011994:Recombinant Proteins; D013972:Thyrotropin; D013954:Thyroglobulin